TrialSignal
Clinical trial intelligence report
A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01835236
Status
COMPLETED
Phase
Phase II
Sponsor
Swiss Cancer Institute
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates a novel treatment strategy for HER2-positive metastatic breast cancer, comparing a chemotherapy-free regimen of trastuzumab and pertuzumab followed by T-DM1 against a chemotherapy-inclusive regimen. The study aims to determine if the new strategy offers similar or improved efficacy and tolerability compared to standard treatments.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01835236
Indication
Metastatic Breast Cancer
Modality
monoclonal antibody
Target
HER2-positive Metastatic Breast Cancer
Intervention
Trastuzumab, Pertuzumab, Paclitaxel, Vinorelbine, T-DM1
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.